Bionomics Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
19,198.30
6,670.20
7,986.70
18,449.20
3,753.50
SG&A Expense
21,481.80
31,241.60
35,080.00
30,766.00
31,053.40
EBIT
3,784.50
26,284.90
-
14,059.40
28,967.70
Unusual Expense
-
168.00
1,112.40
159.00
331.90
Non Operating Income/Expense
244.30
2,000.20
1,607.40
1,699.60
2,364.90
Interest Expense
582.00
762.50
1,735.90
1,811.20
1,725.90
Pretax Income
3,558.70
24,266.70
26,820.50
13,126.30
32,815.50
Income Tax
6,765.30
7,317.30
10,228.10
6,376.70
7,729.90
Consolidated Net Income
3,206.60
16,949.40
16,592.40
6,749.60
25,085.60
Net Income
3,206.60
16,949.40
16,592.40
6,749.60
25,085.60
Net Income After Extraordinaries
3,206.60
16,949.40
16,592.40
6,749.60
25,085.60
Net Income Available to Common
3,206.60
16,949.40
16,592.40
6,749.60
25,085.60
EPS (Basic)
0.01
0.04
0.04
0.01
0.05
Basic Shares Outstanding
416,906.30
417,606.90
457,258.60
481,350.30
482,286.60
EPS (Diluted)
0.01
0.04
0.04
0.01
0.05
Diluted Shares Outstanding
420,329.10
417,606.90
457,258.60
481,350.30
482,286.60
EBITDA
2,283.60
24,571.40
27,093.40
12,316.80
27,299.90
Non-Operating Interest Income
563.60
948.50
1,226.50
1,203.70
574.90

About Bionomics

View Profile
Address
31 Dalgleish Street
Thebarton South Australia (SA) 5031
Australia
Employees -
Website http://www.bionomics.com.au
Updated 07/08/2019
Bionomics Ltd. is a clinical stage biopharmaceutical company, which discovers and develops therapeutics for cancer and diseases of the central nervous system. The company operates through following segments: Drug Discovery and Development, and Contract Services. The Drug discovery and development segment engages in the discovery, development and commercialization of compounds to match a target product profile.